Source: Pharmac
What we’re doing
PHARMAC is pleased to announce the approval of a listing agreement for endomechanical and electrosurgical products, and surgical suction, chest and wound drainage medical devices with Stryker New Zealand Limited (“Stryker”) for listing on the Pharmaceutical Schedule from 1 August 2020.
In summary this will result in:
- Stryker’s products being listed in Part III of Section H of the Pharmaceutical Schedule from 1 August 2020 under a national agreement that all DHBs may purchase under (“Agreement”);
- DHBs being able to continue to purchase other suppliers’ brands of endomechanical and electrosurgical, and surgical suction, chest and wound drainage medical devices.
Any changes to the original proposal?
This decision was subject to a consultation letter dated 11 June 2020.
No changes were made to the Agreement following consultation feedback.
Who we think will be most interested
- DHB staff:
- Clinical engineers
- Surgeons
- Perioperative staff
- Theatre staff
- Procurement and supply chain personnel
- Surgical and general ward staff
- Central sterile services personnel
- Suppliers and Wholesalers
Details about this decision
In 2018 PHARMAC issued Requests for Proposals (RFPs) for:
The RFPs were for non-exclusive national agreements for listing on the Pharmaceutical Schedule.
After completing the RFP evaluation processes, and consulting on the provisional Agreement reached with Stryker, PHARMAC has decided to list Stryker’s medical devices in Part III of Section H of the Pharmaceutical Schedule from 1 August 2020.
DHBs can continue to choose which endomechanical and electrosurgical, and surgical suction, chest and wound drainage products they purchase, including those from other suppliers. DHBs that purchase endomechanical and electrosurgical, and surgical suction, chest and wound drainage products from Stryker must do so under the terms and conditions, including pricing, in the Agreement, from 1 August 2020.
The Agreement includes terms and conditions for training and education to be provided by Stryker on the appropriate use of its products, which is to be provided at times as agreed with individual DHBs.
Our response to what you told us
We appreciate the time people took to respond to this consultation.
A summary of the main themes raised in feedback and our responses to the feedback are set out below:
|
Theme |
Comment |
|---|---|
|
Financial impact of the decision may be underestimated due to missing sales data |
Noted. Updated information has been requested from the supplier. |
If you have any questions about this decision, you can email us at enquiry@pharmac.govt.nz; or call our toll-free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.
Last updated: 9 July 2020
